Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-04-04 | BioXcel Therapeutics, Inc. | O'Neill Vincent
(See Remarks) |
S | Common Stock | D | 165 | $2.62 - $2.62 | $432 |
| 2024-04-04 | BioXcel Therapeutics, Inc. | Mehta Vimal
(CEO and President) |
S | Common Stock | D | 5268 | $2.62 - $2.62 | $13,822 |
| 2024-04-04 | BioXcel Therapeutics, Inc. | Steinhart Richard I
(Chief Financial Officer) |
S | Common Stock | D | 1069 | $2.63 - $2.63 | $2,816 |
| 2024-04-04 | BioXcel Therapeutics, Inc. | Wiley Matthew T.
(CHIEF COMMERCIAL OFFICER) |
S | Common Stock | D | 1008 | $2.64 - $2.64 | $2,656 |
| 2024-04-04 | BioXcel Therapeutics, Inc. | Rodriguez Javier
(See Remarks) |
S | Common Stock | D | 1012 | $2.64 - $2.64 | $2,667 |
| 2024-04-04 | BioXcel Therapeutics, Inc. | Yocca Frank
(Chief Scientific Officer) |
S | Common Stock | D | 1067 | $2.63 - $2.63 | $2,811 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |